| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
207,851,000 |
| Market
Cap: |
11.53(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$32.18 - $59.82 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Catalent is a holding company. Through its subsidiaries, Co. has two operating and reporting segments: Biologics and Pharma and Consumer Health. The Biologics segment provides development and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells; and vaccines. The Pharma and Consumer Health segment comprises Co.'s capabilities for oral solids, softgel formulations, Zydis® fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms; and clinical trial development and supply services.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,000 |
1,000 |
| Total Buy Value |
$0 |
$0 |
$49,980 |
$49,980 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
387 |
387 |
11,063 |
116,582 |
| Total Sell Value |
$21,749 |
$21,749 |
$512,581 |
$11,151,362 |
| Total People Sold |
1 |
1 |
12 |
18 |
| Total Sell Transactions |
1 |
1 |
25 |
69 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Castellano Thomas P |
SVP, Chief Financial Officer |
• – – |
2021-08-26 |
4 |
A |
$0.00 |
$0 |
D/D |
4,273 |
19,798 |
|
- |
|
| Maselli Alessandro |
President & COO |
• – – |
2021-08-26 |
4 |
A |
$0.00 |
$0 |
D/D |
8,008 |
29,642 |
|
- |
|
| Pravda Ricardo |
SVP & Chief HR Officer |
• – – |
2021-08-26 |
4 |
A |
$0.00 |
$0 |
D/D |
2,030 |
13,527 |
|
- |
|
| Fasman Steven L |
SVP & General Counsel |
• – – |
2021-08-26 |
4 |
A |
$0.00 |
$0 |
D/D |
11,566 |
80,699 |
|
- |
|
| Hopson Ricky |
VP, Chief Accounting Officer |
• – – |
2021-08-26 |
4 |
A |
$0.00 |
$0 |
D/D |
4,317 |
20,869 |
|
- |
|
| Arnold Jonathan |
Pres. Oral & Specialty Deliv. |
• – – |
2021-08-26 |
4 |
A |
$0.00 |
$0 |
D/D |
7,830 |
47,197 |
|
- |
|
| Schmidt Kay A |
SVP, Technical Operations |
• – – |
2021-08-26 |
4 |
A |
$0.00 |
$0 |
D/D |
2,590 |
16,794 |
|
- |
|
| Pravda Ricardo |
SVP & Chief HR Officer |
• – – |
2021-07-26 |
4 |
A |
$0.00 |
$0 |
D/D |
885 |
11,497 |
|
- |
|
| Pravda Ricardo |
SVP & Chief HR Officer |
• – – |
2021-07-26 |
4 |
AS |
$113.05 |
$51,777 |
D/D |
(458) |
10,612 |
|
13% |
|
| Fasman Steven L |
SVP & General Counsel |
• – – |
2021-07-26 |
4 |
A |
$0.00 |
$0 |
D/D |
1,770 |
69,133 |
|
- |
|
| Fasman Steven L |
SVP & General Counsel |
• – – |
2021-07-26 |
4 |
AS |
$113.05 |
$175,114 |
D/D |
(1,549) |
67,363 |
|
13% |
|
| Arnold Jonathan |
Pres. Oral & Specialty Deliv. |
• – – |
2021-07-26 |
4 |
A |
$0.00 |
$0 |
D/D |
885 |
39,367 |
|
- |
|
| Arnold Jonathan |
Pres. Oral & Specialty Deliv. |
• – – |
2021-07-26 |
4 |
AS |
$113.05 |
$13,566 |
D/D |
(120) |
38,482 |
|
13% |
|
| Chiminski John R |
Chair & CEO |
• • – |
2021-07-26 |
4 |
A |
$0.00 |
$0 |
D/D |
16,461 |
168,942 |
|
- |
|
| Chiminski John R |
Chair & CEO |
• • – |
2021-07-26 |
4 |
AS |
$113.05 |
$1,259,038 |
D/D |
(11,137) |
152,481 |
|
13% |
|
| Schmidt Kay A |
SVP, Technical Operations |
• – – |
2021-07-26 |
4 |
A |
$0.00 |
$0 |
D/D |
885 |
14,204 |
|
- |
|
| Schmidt Kay A |
SVP, Technical Operations |
• – – |
2021-07-26 |
4 |
AS |
$113.05 |
$61,838 |
D/D |
(547) |
13,319 |
|
13% |
|
| Gennadios Aristippos |
President Softgel & Oral Tech |
• – – |
2021-07-26 |
4 |
A |
$0.00 |
$0 |
D/D |
885 |
51,735 |
|
- |
|
| Gennadios Aristippos |
President Softgel & Oral Tech |
• – – |
2021-07-26 |
4 |
AS |
$113.05 |
$52,568 |
D/D |
(465) |
50,850 |
|
13% |
|
| Flynn Karen |
Pres. Biologics & CCO |
• – – |
2021-07-26 |
4 |
A |
$0.00 |
$0 |
D/D |
1,151 |
35,695 |
|
- |
|
| Gunther Scott |
SVP, Quality & Reg. Affairs |
• – – |
2021-07-26 |
4 |
A |
$0.00 |
$0 |
D/D |
753 |
16,183 |
|
- |
|
| Gunther Scott |
SVP, Quality & Reg. Affairs |
• – – |
2021-07-26 |
4 |
AS |
$113.02 |
$121,967 |
D/D |
(1,079) |
15,430 |
|
13% |
|
| Whitlow Ricci S |
President, CSS |
• – – |
2021-07-26 |
4 |
A |
$0.00 |
$0 |
D/D |
531 |
3,107 |
|
- |
|
| Grippo Michael J |
SVP, Strategy & Corp. Dev. |
• – – |
2021-07-26 |
4 |
A |
$0.00 |
$0 |
D/D |
974 |
17,579 |
|
- |
|
| Grippo Michael J |
SVP, Strategy & Corp. Dev. |
• – – |
2021-07-26 |
4 |
AS |
$113.05 |
$50,986 |
D/D |
(451) |
16,605 |
|
13% |
|
821 Records found
|
|
Page 11 of 33 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.51 (0.93%) 
